Chardan lowered the firm’s price target on Passage Bio (PASG) to $6 from $7 and keeps a Buy rating on the shares. The firm updated the company’s model for the Q4 report. Data from patients treated with dose 1 of PBFT02 continue to look encouraging in frontotemporal dementia with GRN mutations, with patient dosing underway for a lower dose, the analyst tells investors in a research note. The firm sees upcoming catalysts for the shares, including updated data from the trial in the second half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PASG:
- Passage Bio: Promising Clinical Progress and Strong Financial Health Support Buy Rating
- Passage Bio Reports 2024 Financial Results and Program Advances
- Passage Bio reports FY24 EPS ($1.07) vs ($1.86) last year
- Passage Bio announces data from upliFT-D study in FTD-GRN, provides update
- Passage Bio Restructures and Extends Cash Runway